Successful IPO of eXoZymes
Despite challenging market conditions for small IPOs, MDB successfully launched eXoZymes in November, marking their 17th company brought public.
Increased Shareholder and Account Growth
The shareholder count increased by 12% to 1,800, and the launch of MDB Direct saw 456 new investor accounts by end of the year.
Partnership and Expansion Efforts
MDB is expanding partnerships with RIAs, angel groups, and clubs like the Oxford Club to broaden their investor community.
HeartBeam and ClearSign Updates
HeartBeam is making progress with its FDA submissions, and ClearSign is gaining traction in the hydrogen market, both showing potential for future growth.